RESULTS OF THE CLINICAL TRIAL FOURIER. NEW OPPORTUNITIES FOR TREATMENT OF VERY HIGH CARDIOVASCULAR RISK PATIENTS
Advisory Board of Russian Society of Cardiology (RSC), Russian National Atherosclerosis Society (RNAS), Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention (RSCRSP)
Saved in:
Main Author: | Advisory Board |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2017-06-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2320 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01) -
Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023-04-01) -
EXPERIENCE WITH THE USE OF EVOLOCUMAB THERAPY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (IN KARELIA REPUBLIC)
by: V. A. Korneva, et al.
Published: (2020-06-01) -
TREATMENT OF PATIENTS WITH SEVERE DYSLIPIDEMIA IN REAL CLINICAL PRACTICE
by: V. A. Korneva, et al.
Published: (2015-09-01) -
Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council
by: M. V. Ezhov, et al.
Published: (2021-03-01)